Reports > Consumer Goods And Retailing > Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Report
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Size, Share, Industry Trends and Forecast to 2033
This report provides an in-depth analysis of the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market. It includes key insights, market size forecasts, and growth projections for the years 2023 to 2033.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $35.60 Billion |
| CAGR (2023-2033) | 7.2% |
| 2033 Market Size | $72.77 Billion |
| Top Companies | Lonza Group AG, Catalent, Inc., WuXi AppTec, Samsung Biologics, Thermo Fisher Scientific |
| Last Modified Date | 15 Nov 2024 |
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Report (2023 - 2033)
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Overview
What is the Market Size & CAGR of Pharmaceutical Contract Development And Manufacturing Organization Cdmo market in 2023?
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Industry Analysis
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Segmentation and Scope
Request a custom research report for industry.
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Analysis Report by Region
Europe Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Report:
Europe's CDMO market will grow substantially from $11.87 billion in 2023 to $24.26 billion by 2033. Innovations in drug development, coupled with stringent regulatory environments, contribute to the market's robustness.Asia Pacific Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Report:
The Asia Pacific region is witnessing rapid growth, with the market size projected to reach $12.47 billion by 2033, up from $6.10 billion in 2023. This growth can be attributed to an increase in healthcare expenditure, a rising number of biopharmaceutical companies, and favorable government policies promoting foreign investment.North America Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Report:
North America holds the largest market share, valued at $12.67 billion in 2023, projected to reach $25.89 billion by 2033. The mature pharmaceutical sector, along with the presence of major CDMO players, drives significant demand for outsourcing in this region.South America Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Report:
In South America, the CDMO market is expected to grow from $0.63 billion in 2023 to $1.30 billion by 2033. The emerging markets in this region are realizing the importance of outsourcing to enhance efficiency in drug development and manufacturing processes.Middle East & Africa Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Report:
The CDMO market in the Middle East and Africa is anticipated to grow from $4.33 billion in 2023 to $8.86 billion by 2033. The growth is fueled by increasing investments in healthcare infrastructure and rising demand for quality health services.Request a custom research report for industry.
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Analysis By Service Type
Global Pharmaceutical CDMO Market, By Service Type Market Analysis (2023 - 2033)
Development services dominate the Pharmaceutical CDMO market with a share of 62.19% in 2023, expected to grow to 62.19% by 2033. Manufacturing services hold a substantial market share as well, contributing 28.35% in 2023 and projected to maintain that percentage by 2033. Other services account for the remainder, experiencing growth commensurate with industry demands.
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Analysis By Therapy Area
Global Pharmaceutical CDMO Market, By Therapy Area Market Analysis (2023 - 2033)
In 2023, oncology and neurology are the leading therapy areas within the CDMO market, with sizes of $16.28 billion and $7.92 billion, expected to rise to $33.27 billion and $16.18 billion respectively by 2033. Other therapy areas, such as cardiology and infectious diseases, also show significant growth potentials, expanding their market sizes and benefits over the forecast period.
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Analysis By End User
Global Pharmaceutical CDMO Market, By End-User Market Analysis (2023 - 2033)
Pharmaceutical companies and biopharma lead the market demand, with shares of 24.93% and 50.19% in 2023, respectively. The academic institutions represent a specialized segment, catering to research needs and driving innovation in developing therapies. Contract Research Organizations (CROs) are also a significant part of the market, facilitating essential partnerships between companies.
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Analysis By Geographical Reach
Global Pharmaceutical CDMO Market, By Geographical Reach Market Analysis (2023 - 2033)
Local CDMOs dominate with an 82.17% market share in 2023, expected to maintain dominance due to their operational efficiencies and regulatory knowledge. In contrast, Global CDMOs occupy approximately 17.83% of the market share, illustrating potential for growth as they seek to expand into emerging markets.
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Pharmaceutical Contract Development And Manufacturing Organization Cdmo Industry
Lonza Group AG:
Lonza is a Swiss multinational that offers comprehensive services to pharmaceutical and biotechnology industries, focusing on cell and gene therapies and complex dosage forms.Catalent, Inc.:
Catalent is a leading provider of advanced delivery technologies, development, and manufacturing solutions for pharmaceutical customers.WuXi AppTec:
WuXi AppTec provides comprehensive and integrated solutions to its clients in the pharmaceutical and biotechnology sectors.Samsung Biologics:
Samsung Biologics specializes in biopharmaceutical contract manufacturing, providing end-to-end solutions for drug development lifecycles.Thermo Fisher Scientific:
Through its acquisition of Patheon, Thermo Fisher has positioned itself as a global leader in the pharmaceutical CDMO sector, offering comprehensive services across multiple modalities.We're grateful to work with incredible clients.
